Roivant unveils new mosliciguat pipeline program

Roivant Sciences (Nasdaq: ROIV) today announced its previously undisclosed pipeline program mosliciguat, a potential first-in-class, inhaled, once-daily sGC activator with targeted delivery to the lungs via dry powder inhaler, at Pulmovant.

Pulmovant presented data from the proof-of-concept Phase Ib ATMOS study during the ERS Congress in Vienna, Austria.

• In      the Phase Ib ATMOS study, presented today is a single dose of inhaled      mosliciguat in pulmonary hypertension (PH) patients (N=38) led to      sustained, clinically-meaningful mean-max reductions in pulmonary vascular      resistance (PVR) of up to ~38%, one of the highest reductions seen in PH      trials to date.
• Once-daily      dosing via dry powder inhaler (DPI) was generally well-tolerated, with low      rates of treatment-emergent adverse events (TEAEs).
• The      global Phase II “PHocus” study of mosliciguat in ~120 patients with PH-ILD      is expected to begin imminently.